At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 286 enrolled
Drug / intervention
Nemolizumab 30 mg +1 moredrug
Likely dose
Nemolizumab 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
In Brief
A Phase 3 clinical trial evaluating Nemolizumab 30 mg and Placebo for Prurigo Nodularis. Completed, enrolled 286 participants across 100 sites in 10 countries.
Detailed Summary
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis
CountriesAustria, Canada, Denmark, Germany, Hungary, Italy, Poland, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionNov 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedAug 6, 2020
Enrollment StartSep 11, 2020
Primary CompletionNov 11, 2022
Study CompletionFeb 21, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.9 years ago
Interventions
Nemolizumab 30 mgdrug
Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
Placebodrug
Participants received matching placebo as SC injection.